For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not ...
One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), ...
With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...
Germany's Bayer said Wednesday it was confident of "significantly" containing long-running legal woes related to a weedkiller ...
The Healthy @Reader's Digest on MSN
Study: Low-Dose Aspirin Could Lower Heart Risk in People With This Condition
Leading heart experts say the results were "somewhat surprising," and their discovery could warrant a conversation with your ...
Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group.
Bayer is working with custom algorithm firm Chalice AI and data partner Snowflake to create audiences for targeting ads.
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today ...
Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes. The FDA signed off on Bayer’s oral therapy elinzanetant for the treatment ...
The United States Food and Drug Administration (FDA) has approved Bayer’s drug to ease hot flashes in menopausal women, the German company said on Oct 24, a welcome development following the regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback